LongRiver Investments

Rona Therapeutics is an innovative RNA therapeutics platform focused on the discovery, development, and commercialization of modular and programmable RNA medicines. The company specializes in oligonucleotide therapies, RNA editing, and polymeric molecules, aiming to create transformative RNA therapies that can significantly impact disease treatment across various therapeutic areas. Rona Therapeutics is committed to developing proprietary technologies that enhance the specificity, stability, and longevity of therapeutic effects. To support its mission, the company is establishing state-of-the-art facilities to advance nucleic acid synthesis, delivery platforms, and RNA biology. Through its efforts, Rona Therapeutics seeks to improve patient health outcomes and foster an environment conducive to innovation and excellence in RNA medicine.

Oukejian specializes in researching and developing innovative large-molecule drugs for prevalent fundus diseases.

Ouroboros Medicines is a biotechnology company dedicated to immunology, focusing on treating chronic immune-mediated illnesses. It specializes in developing immune reset treatments, using a therapeutic platform that employs T cell engager antibodies to target and deplete specific pathogenic cells. This approach aims to provide extended remissions for patients, without the need for ongoing immunosuppression. The company's strength lies in its integration of scientific knowledge and proven track record in progressing cell-depleting treatments through clinical trials, supported by a robust pipeline.

Zhilong New Materials is a Sino-foreign joint venture semiconductor material innovation enterprise that researches, produces, and sells semiconductor display sputtering targets and semiconductor photovoltaic targets.

Henghui Keyuan is the next generation of disruptors in the electrochemical energy storage battery business.

Rona Therapeutics is an innovative RNA therapeutics platform focused on the discovery, development, and commercialization of modular and programmable RNA medicines. The company specializes in oligonucleotide therapies, RNA editing, and polymeric molecules, aiming to create transformative RNA therapies that can significantly impact disease treatment across various therapeutic areas. Rona Therapeutics is committed to developing proprietary technologies that enhance the specificity, stability, and longevity of therapeutic effects. To support its mission, the company is establishing state-of-the-art facilities to advance nucleic acid synthesis, delivery platforms, and RNA biology. Through its efforts, Rona Therapeutics seeks to improve patient health outcomes and foster an environment conducive to innovation and excellence in RNA medicine.

Ronovo Surgical is an emerging medtech company dedicated to advancing minimally invasive surgery (MIS) through innovative robotic technology. The company has developed a soft tissue surgery robot platform that utilizes next-generation robotics and advanced digital solutions to enhance surgical precision and efficiency. By focusing on various surgical specialties, Ronovo aims to optimize patient outcomes and improve health economics, particularly within the Chinese medical industry. Their efforts are designed to transform surgical care by delivering more effective and less invasive surgical options.

Nanjing Tuge Healthcare Co., Ltd., established in 2018 and headquartered in Nanjing, China, specializes in the research and development of advanced medical technologies. The company is particularly focused on the industrialization of 4K endoscopic imaging equipment, which enhances visual clarity during medical procedures. Additionally, Tuge Medical Technology is engaged in the creation of digital intelligent operating rooms, aimed at improving surgical efficiency and patient outcomes. Through its innovative solutions, Tuge Medical Technology seeks to advance the capabilities of healthcare facilities and enhance the overall quality of medical care.

Huiyueyan Biotechnology is an innovative biomaterials firm that focuses on medical microspheres, degradable materials, and sustained-release technology.

Ronovo Surgical is an emerging medtech company dedicated to advancing minimally invasive surgery (MIS) through innovative robotic technology. The company has developed a soft tissue surgery robot platform that utilizes next-generation robotics and advanced digital solutions to enhance surgical precision and efficiency. By focusing on various surgical specialties, Ronovo aims to optimize patient outcomes and improve health economics, particularly within the Chinese medical industry. Their efforts are designed to transform surgical care by delivering more effective and less invasive surgical options.

Allorion Therapeutics is a small molecule therapeutic development company specializing in the treatment of cancer and autoimmune diseases. With operations in Natick, Massachusetts, and Guangzhou, China, Allorion focuses on creating mutant selective and isoform-specific drugs through innovative methods targeting established medical challenges. By concentrating on enhancing drug efficacy and preventing resistance in patients, the company aims to improve therapeutic outcomes in these critical areas of healthcare.

Ronovo Surgical is an emerging medtech company dedicated to advancing minimally invasive surgery (MIS) through innovative robotic technology. The company has developed a soft tissue surgery robot platform that utilizes next-generation robotics and advanced digital solutions to enhance surgical precision and efficiency. By focusing on various surgical specialties, Ronovo aims to optimize patient outcomes and improve health economics, particularly within the Chinese medical industry. Their efforts are designed to transform surgical care by delivering more effective and less invasive surgical options.

Sironax is a clinical-stage biotechnology company based in Beijing, China, founded in 2017. The company specializes in developing innovative products and treatments targeting age-related degenerative diseases. Sironax focuses on key mechanisms such as regulated cell death, neuroprotective pathways, and neuroinflammation, conducting research on apoptosis and other cell death pathways. By advancing pharmaceutical solutions for inflammatory and neurodegenerative diseases, Sironax aims to transform the treatment landscape and enhance the quality of life for millions of patients and their families globally.

Device42, Inc. is a software company that specializes in providing solutions for system, network, and data center engineers, as well as IT managers. Founded in 2010 and headquartered in West Haven, Connecticut, with an additional office in Boston, Massachusetts, Device42 offers a comprehensive suite of tools designed for IT inventory management, patch panel cable management, data center power management, and IP address tracking. Its platform includes essential features such as Configuration Management Database (CMDB), Application Dependency Mapping (ADM), and a DCIM Software Marketplace, all aimed at helping organizations maintain accurate inventories of both IP-based and non-IP assets. The software facilitates various IT operations, compliance auditing, migration, and modernization processes, making it easier for clients to manage hybrid IT environments and execute successful cloud migrations while ensuring compliance with internal and external regulations.